Praxis Precision Medicines, Inc. Common Stock (PRAX) is a publicly traded Healthcare sector company. As of November 16, 2026, PRAX trades at $332.50 with a market cap of $9.17B and a P/E ratio of -19.38. PRAX moved +1.33% today. Year to date, PRAX is +14.57%; over the trailing twelve months it is +84.26%. Its 52-week range spans $26.70 to $392.70. Analyst consensus is strong buy with an average price target of $728.33. Rallies surfaces PRAX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Praxis targets FDA action dates for relutrigine and ulixacaltamide: Praxis is targeting FDA action dates of December 27, 2026, for relutrigine and January 29, 2027, for ulixacaltamide. Its peak-sales guidance remains $10 billion for ulixacaltamide, $5 billion for relutrigine, $4 billion for vormatrigine and $1 billion for elsunersen.
| Metric | Value |
|---|---|
| Price | $332.50 |
| Market Cap | $9.17B |
| P/E Ratio | -19.38 |
| EPS | $-13.48 |
| Dividend Yield | 0.00% |
| 52-Week High | $392.70 |
| 52-Week Low | $26.70 |
| Volume | 19 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-303.27M |
| Gross Margin | 0.00% |
12 analysts cover PRAX: 0 strong buy, 11 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $728.33.